Back to the main directory
Press Release
- America’s Car-Mart, Inc. Schedules Second Quarter Fiscal Year 2025 Results and Conference Call by GlobeNewsWire
- MKS Instruments Announces Appointment of Wissam Jabre to its Board of Directors by GlobeNewsWire
- IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting by GlobeNewsWire
- MKS Instruments Declares Quarterly Cash Dividend by GlobeNewsWire
- Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma by GlobeNewsWire
- C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting by GlobeNewsWire
- Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting by GlobeNewsWire
- NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024 by GlobeNewsWire
- Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition by GlobeNewsWire
- Innovative Food Holdings, Inc. Announces Q3 2024 Earnings Call by GlobeNewsWire
- Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations by GlobeNewsWire
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results by GlobeNewsWire
- Global-e to Announce Financial Results for the Third Quarter 2024 on November 20, 2024 by GlobeNewsWire
- EQS-News: Greenliant High Endurance NVMe SSDs on Display at electronica 2024 by EQS Group AG
- Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition by GlobeNewsWire
- Anaergia to Strengthen Its Market Position With New Office in Japan by BusinessWire
- Satisfaction With Provider Services Edges Up, as Companies Seek More Innovation, ISG Study Shows by BusinessWire
- Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting by GlobeNewsWire
- Form 8.3 - The Vanguard Group, Inc.: Smith (DS) plc by EQS Group AG
- Form 8.3 - The Vanguard Group, Inc.: SEGRO plc by EQS Group AG
- TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition by GlobeNewsWire
- Form 8.3 - The Vanguard Group, Inc.: International Paper Company by EQS Group AG
- Storaktionærmeddelelse by GlobeNewsWire
- Crown Announces Suspension of Equity Line of Credit by GlobeNewsWire
- Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920 by GlobeNewsWire
- Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma by GlobeNewsWire
- Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting by GlobeNewsWire
- Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting by GlobeNewsWire
- Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting by GlobeNewsWire
- Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting by GlobeNewsWire
- Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting by GlobeNewsWire
- Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma by GlobeNewsWire
- Revolution Medicines to Participate in Upcoming Investor Conferences by GlobeNewsWire
- Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13 by GlobeNewsWire
- Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting by GlobeNewsWire
- Blink to establish a £100 million Special Purpose Vehicle to Drive Electric Vehicle Charger Investments, Engaging Axxeltrova Capital as First Funding Partner by GlobeNewsWire
- UFP Technologies Announces Record Q3 2024 Results by GlobeNewsWire
- Seanergy Maritime Reports Third Quarter and Nine Months Financial Results for the Periods Ended September 30, 2024 by GlobeNewsWire
- EQS-News: Geratherm Medical AG: Verkauf der apoplex medical technologies GmbH erfolgreich abgeschlossen by EQS Group AG
- Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates by GlobeNewsWire
- Quantum-Si to Participate in Upcoming Investment Conferences by BusinessWire
- Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma by GlobeNewsWire
- Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy by GlobeNewsWire
- Form 8.3 - The Vanguard Group, Inc.: AngloGold Ashanti plc by EQS Group AG
- Form 8.3 - The Vanguard Group, Inc.: Hargreaves Lansdown plc by EQS Group AG
- Form 8.3 - The Vanguard Group, Inc.: StoneX Group Inc. by EQS Group AG
- CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity by GlobeNewsWire
- Storaktionærmeddelelse by GlobeNewsWire
- Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting by GlobeNewsWire
- Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds by GlobeNewsWire